Cargando…

Post-Vaccination Neutralization Responses to Omicron Sub-Variants

Background: The emergence of the Omicron variant (B.1.1.529), which correlated with dramatic losses in cross-neutralization capacity of post-vaccination sera, raised concerns about the effectiveness of COVID-19 vaccines against infection and disease. Several clinically relevant sub-variants subseque...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobsen, Henning, Katzmarzyk, Maeva, Higdon, Melissa M., Jiménez, Viviana Cobos, Sitaras, Ioannis, Bar-Zeev, Naor, Knoll, Maria Deloria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607453/ https://www.ncbi.nlm.nih.gov/pubmed/36298622 http://dx.doi.org/10.3390/vaccines10101757

Ejemplares similares

Post-vaccination T cell immunity to omicron
por: Jacobsen, Henning, et al.
Publicado: (2022)

Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant
por: Sitaras, Ioannis, et al.
Publicado: (2022)

Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2
por: Jacobsen, Henning, et al.
Publicado: (2023)

Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera
por: Jacobsen, Henning, et al.
Publicado: (2022)

Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of post-vaccination sera
por: Katzmarzyk, Maeva, et al.
Publicado: (2023)

Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant
por: Higdon, Melissa M, et al.
Publicado: (2022)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
por: Peng, Weiyu, et al.
Publicado: (2023)

Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization
por: Feikin, Daniel R., et al.
Publicado: (2023)

Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine
por: Debes, Amanda K., et al.
Publicado: (2022)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023)

Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine
por: Debes, Amanda K., et al.
Publicado: (2022)

Neutralization, effector function and immune imprinting of Omicron variants
por: Addetia, Amin, et al.
Publicado: (2023)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

COVID-19 vaccines: early success and remaining challenges
por: Bar-Zeev, Naor, et al.
Publicado: (2020)

Expecting the unexpected with COVID-19 vaccines
por: Bar-Zeev, Naor, et al.
Publicado: (2021)

Population science with individual-level data make for better policies
por: Bar-Zeev, Naor, et al.
Publicado: (2021)

Human papillomavirus vaccination strategies for accelerating action towards cervical cancer elimination
por: Shet, Anita, et al.
Publicado: (2023)

Pragmatic trials to inform policy decisions and planning
por: Bar-Zeev, Naor, et al.
Publicado: (2023)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
por: Zhao, Xin, et al.
Publicado: (2022)

Neutralization and Stability of SARS-CoV-2 Omicron Variant
por: Zeng, Cong, et al.
Publicado: (2021)

Encouraging results from phase 1/2 COVID-19 vaccine trials
por: Bar-Zeev, Naor, et al.
Publicado: (2020)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations
por: Jacobsen, Henning, et al.
Publicado: (2022)

Plasma neutralization properties of the SARS-CoV-2 Omicron variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022)

Neutralization susceptibility of Omicron lineages
por: Minton, Kirsty
Publicado: (2022)

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns
por: Abassi, Leila, et al.
Publicado: (2023)

Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant
por: Khan, Khadija, et al.
Publicado: (2022)

Measuring indirect effects of rotavirus vaccine in low income countries
por: Bennett, Aisleen, et al.
Publicado: (2016)

Welcome evidence of vaccine impact in the Pacific
por: Saketa, Salanieta T, et al.
Publicado: (2020)

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2023)

Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
por: Xu, Ailan, et al.
Publicado: (2022)

The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge
por: Bronstein, Yotam, et al.
Publicado: (2022)

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
por: Touret, Franck, et al.
Publicado: (2023)

Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
por: Marcotte, Harold, et al.
Publicado: (2022)

Adherence to management guidelines for growth faltering and anaemia in remote dwelling Australian Aboriginal infants and barriers to health service delivery
por: Bar-Zeev, Sarah J, et al.
Publicado: (2013)

SARS-CoV-2 Omicron (B.1.1.529) Variant: Corticosteroids Treatment/Respiratory Coinfection
por: Elkoshi, Zeev
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tferi24i3rqhkse972i029uurm